Last reviewed · How we verify
Tamsulosin - 1 week
At a glance
| Generic name | Tamsulosin - 1 week |
|---|---|
| Sponsor | Hackensack Meridian Health |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Post-operative Urinary Retention (POUR) Following Thoracic Surgery (PHASE1, PHASE2)
- Deprescribing Tamsulosin in Older Men (PHASE4)
- Medical Stone Expulsive Therapy for Acutely Obstructed Ureteric Calculi (PHASE4)
- Medications for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia (PHASE3)
- A Pilot Study of Ultra-High-Dose Hypofractionated or Single-Dose Radiotherapy for Intermediate Risk Prostate Cancer (PHASE2)
- Comparing the Efficiency of Two Approaches in Patients at Risk of Developing Intraoperative Floppy Iris Syndrome (PHASE4)
- Clinical Study of Ningmitai Capsule on Promoting the Passage of Residual Fragments After Ureteroscopic Lithotripsy (PHASE4)
- Efficacy and Safety of Ningmitai Capsule in Patients With Chronic Prostatitis/Chronic Pelvic Pain Syndrome (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tamsulosin - 1 week CI brief — competitive landscape report
- Tamsulosin - 1 week updates RSS · CI watch RSS
- Hackensack Meridian Health portfolio CI